1. Home
  2. ANIX

as of 05-08-2026 2:32pm EST

$2.97
+$0.01
+0.34%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Founded: 1982 Country:
United States
United States
Employees: N/A City: SAN JOSE
Market Cap: 102.6M IPO Year: 2013
Target Price: $8.67 AVG Volume (30 days): 113.0K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.08 EPS Growth: 12.82
52 Week Low/High: $2.44 - $5.46 Next Earning Date: 05-27-2026
Revenue: $210,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -37.56 Index: N/A
Free Cash Flow: -7188791.0 FCF Growth: N/A

AI-Powered ANIX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 4 days ago

AI Recommendation

hold
Model Accuracy: 61.35%
61.35%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: